At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 89 enrolled
Drug / intervention
cyclophosphamide +2 moredrug
Likely dose
cyclophosphamide 600 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study in Patients With Metastatic or Locally Advanced Breast Cancer to Evaluate the Worth of the Combination of Adriamycin (Doxorubicin), Taxotere (Docetaxel), and Cyclophosphamide (ATC)
In Brief
A Phase 2 clinical trial evaluating cyclophosphamide, Taxotere, and 1 other intervention for Breast Cancer. Completed, enrolled 89 participants across 166 sites in 3 countries.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of doxorubicin, cyclophosphamide, and docetaxel in treating women with stage IIIB or stage IV breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesCanada, Puerto Rico, United States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 1998
Primary CompletionSep 2000
Study CompletionDec 2002
First PostedJun 2003
TodayJul 2026
First PostedJun 27, 2003
Enrollment StartJun 1, 1998
Primary CompletionSep 1, 2000
Study CompletionDec 1, 2002
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 23.0 years ago
Interventions
cyclophosphamidedrug
600 mg/m2, IV, every 3 weeks
Taxoteredrug
60 mg/m2, IV, every 3 weeks
Adriamycindrug
60 mg/m2, IV, every 3 weeks